LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

Search

Novo Nordisk A-S

Atidarymo kaina

SektoriusSveikatos priežiūra

56.49 0.68

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

56.26

Max

56.5

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-2.5B

27B

Pardavimai

-1.2B

77B

P/E

Sektoriaus vid.

14.483

35.724

Pelnas, tenkantis vienai akcijai

6.53

Dividendų pajamingumas

3.03

Pelno marža

34.484

Darbuotojai

78,387

EBITDA

-2.5B

44B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+19.68% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.03%

3.09%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

28B

244B

Ankstesnė atidarymo kaina

55.81

Ankstesnė uždarymo kaina

56.49

Naujienos nuotaikos

By Acuity

84%

16%

358 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bearish Evidence

Novo Nordisk A-S Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-18 13:52; UTC

Pagrindinės rinkos jėgos

GoodRx Partners With Novo Nordisk to Lower Cost of Weight-Loss Drugs

2025-08-18 09:23; UTC

Pagrindinės rinkos jėgos

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

2025-08-18 09:23; UTC

Pagrindinės rinkos jėgos

Novo Nordisk Shares Rise After FDA Approves Wegovy for Liver Disease

2025-08-06 06:52; UTC

Uždarbis

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues -- Update

2025-08-06 06:21; UTC

Uždarbis

Novo Nordisk's Wegovy Weight-Loss Drug Sales Surge Despite Copycat Issues

2025-08-21 08:49; UTC

Uždarbis
Karštos akcijos

Stocks to Watch Thursday: Meta, Coty, Walmart, Novo Nordisk -- WSJ

2025-08-18 09:23; UTC

Karštos akcijos

Stocks to Watch Monday: Novo Nordisk, Soho House, UnitedHealth -- WSJ

2025-08-08 05:32; UTC

Rinkos pokalbiai

Novo Nordisk's Weight-Loss Pill to Dominate Narrative After Eli Lilly's Data -- Market Talk

2025-08-07 11:32; UTC

Uždarbis

Eli Lilly Stock Dives on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

2025-08-07 11:03; UTC

Uždarbis

Eli Lilly Stock Drops on Weight-Loss Pill Data as Earnings Beat Expectations. What to Know. -- Barrons.com

2025-08-07 10:41; UTC

Uždarbis

Eli Lilly Stock Drops on Weight-Loss Pill Data Ahead of Earnings -- Barrons.com

2025-08-06 20:34; UTC

Uždarbis

Eli Lilly Reports Earnings, and Maybe Weight-Loss Pill Data, on Thursday -- Barrons.com

2025-08-06 08:45; UTC

Uždarbis

Novo Nordisk to Cut Costs After Stock Slump. Why Earnings Failed to Impress. -- Barrons.com

2025-08-06 07:19; UTC

Rinkos pokalbiai
Uždarbis

Novo Nordisk Sales in Line, Boosted by One-Off Rebate -- Market Talk

2025-08-06 05:50; UTC

Uždarbis

Novo Nordisk: Gudiance Assumes Macroeconomic, Political Environment Won't Significantly Change Business Conditions During 2025

2025-08-06 05:48; UTC

Uždarbis

Novo Nordisk Declares Interim Dividend of DKK3.75 Vs DKK3.50

2025-08-06 05:46; UTC

Uždarbis

Novo Nordisk Will Continue to Invest in Expanding Direct-to-Patient Initiatives For Wegovy

2025-08-06 05:38; UTC

Uždarbis

Novo Nordisk 2Q Ozempic Drug Sales DKK31.8B Vs DKK28.88B

2025-08-06 05:37; UTC

Uždarbis

Novo Nordisk 2Q Wegovy Drug Sales DKK19.53B Vs DKK11.66B

2025-08-06 05:36; UTC

Uždarbis

Novo Nordisk 2Q Gross Margin 83.3% Vs 84.9%, Op Margin 43.5% Vs 38.1%

2025-08-06 05:35; UTC

Uždarbis

Novo Nordisk: Taking Measures to Sharpen Commercial Execution Further, Ensure Efficiencies in Cost Base

2025-08-06 05:34; UTC

Uždarbis

Novo Nordisk: Continues Global Rollout of Wegovy to More Markets, Investing in Commercial Activities

2025-08-06 05:31; UTC

Uždarbis

Novo Nordisk 2Q Net Pft DKK26.5B

2025-08-06 05:31; UTC

Uždarbis

Novo Nordisk 2Q Oper Pft DKK33.45B

2025-08-06 05:31; UTC

Uždarbis

Novo Nordisk 2Q Sales DKK76.86B

2025-08-05 21:58; UTC

Uždarbis

Novo Nordisk's Earnings Come After a Dramatic Guidance Cut. What to Look for Now. -- Barrons.com

2025-08-05 17:26; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

2025-08-05 15:15; UTC

Uždarbis

Novo Nordisk Stock Catches a Downgrade. The Eli Lilly Threat Is Just One Reason. -- Barrons.com

2025-08-05 10:07; UTC

Rinkos pokalbiai

Novo Nordisk's Facing Challenging Times -- Market Talk

2025-08-01 11:10; UTC

Karštos akcijos

Global Stocks to Watch: Novo Nordisk, AXA, Daimler Truck -- WSJ

Akcijų palyginimas

Kainos pokytis

Novo Nordisk A-S Prognozė

Kainos tikslas

By TipRanks

19.68% į viršų

12 mėnesių prognozė

Vidutinis 67.57 USD  19.68%

Aukščiausias 90 USD

Žemiausias 50 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Novo Nordisk A-S kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

7 ratings

2

Pirkti

5

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

62.63 / 69.23Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

358 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Novo Nordisk A-S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.